RGLS

insider transactions

Regulus Therapeutics Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 365d

Open-market Buys Sells All types

No open-market buys or sells in this period — showing all activity (grants, exercises & gifts).

Other·D
Jun 25, 25

Aker Christopher Ray

Sr. VP & General Counsel

—

1.5M sh · 11 lots

Own -100%
Other·U
Jun 25, 25

Aker Christopher Ray

Sr. VP & General Counsel

—

60.8K sh
Other·D
Jun 25, 25

Aker Christopher Ray

Sr. VP & General Counsel

—

83.1K sh

Own -100%
Other·D
Jun 25, 25

RASTETTER WILLIAM H

Director

—

155.0K sh · 8 lots

Own -100%
Other·D
Jun 25, 25

RASTETTER WILLIAM H

Director

—

57.3K sh

Own -100%
Other·U
Jun 25, 25

RASTETTER WILLIAM H

Director

—

44.3K sh
Other·D
Jun 25, 25

PAPADOPOULOS STELIOS

Director

—

214.5K sh · 9 lots

Own -100%
Other·D
Jun 25, 25

PAPADOPOULOS STELIOS

Director

—

64.6K sh

Own -100%
Other·U
Jun 25, 25

PAPADOPOULOS STELIOS

Director

—

976.3K sh
Other·D
Jun 25, 25

Witz Pascale

Director

—

155.7K sh · 9 lots

Own -100%
Other·D
Jun 25, 25

Witz Pascale

Director

—

67.2K sh

Own -100%
Other·D
Jun 25, 25

Klassen Preston KEY

President & Head of R & D

—

1.9M sh · 5 lots

Own -100%
Other·D
Jun 25, 25

Klassen Preston KEY

President & Head of R & D

—

115.6K sh

Own -100%
Other·D
Jun 25, 25

CALSADA CRISPINA KEY

Chief Financial Officer

—

1.6M sh · 10 lots

Own -100%
Other·D
Jun 25, 25

CALSADA CRISPINA KEY

Chief Financial Officer

—

140.2K sh

Own -100%
Other·D
Jun 25, 25

Nunn Jason Raleigh

Director

—

155.0K sh · 8 lots

Own -100%
Other·D
Jun 25, 25

Nunn Jason Raleigh

Director

—

62.5K sh

Own -100%
Other·D
Jun 25, 25

Hagan Joseph P KEY

Chief Executive Officer

—

4.4M sh · 12 lots

Own -100%
Other·D
Jun 25, 25

Hagan Joseph P KEY

Chief Executive Officer

—

571.6K sh

Own -100%
Other·D
Jun 25, 25

Rosen Hugh

Director

—

155.0K sh · 8 lots

Own -100%
Other·D
Jun 25, 25

Rosen Hugh

Director

—

57.3K sh

Own -100%
Other·U
Jun 25, 25

Rosen Hugh

Director

—

7.0K sh
Other·D
Jun 25, 25

BALTIMORE DAVID

Director

—

303.0K sh · 14 lots

Own -100%
Other·D
Jun 25, 25

BALTIMORE DAVID

Director

—

114.6K sh · 2 lots

Own -100%
Other·U
Jun 25, 25

BALTIMORE DAVID

Director

—

32.6K sh · 2 lots
Other·D
Jun 25, 25

Collier Kathryn J

Director

—

148.7K sh · 6 lots

Own -100%
Other·D
Jun 25, 25

Collier Kathryn J

Director

—

75.6K sh

Own -100%
Other·D
Jun 25, 25

Huang Alice Shih-hou

Director

—

303.0K sh · 14 lots

Own -100%
Other·D
Jun 25, 25

Huang Alice Shih-hou

Director

—

114.6K sh · 2 lots

Own -100%
Other·U
Jun 25, 25

Huang Alice Shih-hou

Director

—

32.6K sh · 2 lots

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 25, 2025	Aker Christopher Ray	Sr. VP & General Counsel	Other D	1.5M11 lots	-100%	—	—
Jun 25, 2025	Aker Christopher Ray	Sr. VP & General Counsel	Other U	60.8K	—	—	—
Jun 25, 2025	Aker Christopher Ray	Sr. VP & General Counsel	Other D	83.1K	-100%	—	—
Jun 25, 2025	RASTETTER WILLIAM H	Director	Other D	155.0K8 lots	-100%	—	—
Jun 25, 2025	RASTETTER WILLIAM H	Director	Other D	57.3K	-100%	—	—
Jun 25, 2025	RASTETTER WILLIAM H	Director	Other U	44.3K	—	—	—
Jun 25, 2025	PAPADOPOULOS STELIOS	Director	Other D	214.5K9 lots	-100%	—	—
Jun 25, 2025	PAPADOPOULOS STELIOS	Director	Other D	64.6K	-100%	—	—
Jun 25, 2025	PAPADOPOULOS STELIOS	Director	Other U	976.3K	—	—	—
Jun 25, 2025	Witz Pascale	Director	Other D	155.7K9 lots	-100%	—	—
Jun 25, 2025	Witz Pascale	Director	Other D	67.2K	-100%	—	—
Jun 25, 2025	Klassen Preston KEY	President & Head of R & D	Other D	1.9M5 lots	-100%	—	—
Jun 25, 2025	Klassen Preston KEY	President & Head of R & D	Other D	115.6K	-100%	—	—
Jun 25, 2025	CALSADA CRISPINA KEY	Chief Financial Officer	Other D	1.6M10 lots	-100%	—	—
Jun 25, 2025	CALSADA CRISPINA KEY	Chief Financial Officer	Other D	140.2K	-100%	—	—
Jun 25, 2025	Nunn Jason Raleigh	Director	Other D	155.0K8 lots	-100%	—	—
Jun 25, 2025	Nunn Jason Raleigh	Director	Other D	62.5K	-100%	—	—
Jun 25, 2025	Hagan Joseph P KEY	Chief Executive Officer	Other D	4.4M12 lots	-100%	—	—
Jun 25, 2025	Hagan Joseph P KEY	Chief Executive Officer	Other D	571.6K	-100%	—	—
Jun 25, 2025	Rosen Hugh	Director	Other D	155.0K8 lots	-100%	—	—
Jun 25, 2025	Rosen Hugh	Director	Other D	57.3K	-100%	—	—
Jun 25, 2025	Rosen Hugh	Director	Other U	7.0K	—	—	—
Jun 25, 2025	BALTIMORE DAVID	Director	Other D	303.0K14 lots	-100%	—	—
Jun 25, 2025	BALTIMORE DAVID	Director	Other D	114.6K2 lots	-100%	—	—
Jun 25, 2025	BALTIMORE DAVID	Director	Other U	32.6K2 lots	—	—	—
Jun 25, 2025	Collier Kathryn J	Director	Other D	148.7K6 lots	-100%	—	—
Jun 25, 2025	Collier Kathryn J	Director	Other D	75.6K	-100%	—	—
Jun 25, 2025	Huang Alice Shih-hou	Director	Other D	303.0K14 lots	-100%	—	—
Jun 25, 2025	Huang Alice Shih-hou	Director	Other D	114.6K2 lots	-100%	—	—
Jun 25, 2025	Huang Alice Shih-hou	Director	Other U	32.6K2 lots	—	—	—

Buy Sell Non-market (grant · exercise · gift)

About RGLS insider trading

This page tracks insider transactions for Regulus Therapeutics Inc. (RGLS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.